BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 28118723)

  • 1. [Treatment with Aromatase Inhibitors in Postmenopausal Women with Breast Cancer and the Possibility of Influencing Side Effects].
    Krásenská M
    Klin Onkol; 2016; 29 Suppl 3():S39-49. PubMed ID: 28118723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors.
    Rugo HS
    Ann Oncol; 2008 Jan; 19(1):16-27. PubMed ID: 17693420
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Circulating Levels of Estradiol in Breast Cancer Patients Treated with Aromatase Inhibitors and Their Clinical Implications].
    Petráková K; Krásenská M; Valík D; Holánek M; Palácová M; Demlová R
    Klin Onkol; 2016; 29 Suppl 3():S50-57. PubMed ID: 28118724
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects].
    de Cremoux P; Diéras V; Poupon MF; Magdelénat H; Sigal-Zafrani B; Fourquet A; Pierga JY
    Bull Cancer; 2004 Dec; 91(12):917-27. PubMed ID: 15634633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ovarian Ablation in Breast Cancer Patients and the Possibility of Influencing Treatment Side Effects].
    Palácová M
    Klin Onkol; 2016; 29 Suppl 3():S29-38. PubMed ID: 28118722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aromatase inhibitors in the adjuvant treatment of postmenopausal women with early breast cancer: Putting safety issues into perspective.
    Conte P; Frassoldati A
    Breast J; 2007; 13(1):28-35. PubMed ID: 17214790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of aromatase inhibitors in the adjuvant setting.
    Perez EA
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):75-89. PubMed ID: 17912638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women.
    Mouridsen HT
    Curr Med Res Opin; 2006 Aug; 22(8):1609-21. PubMed ID: 16870085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients.
    Morales L; Neven P; Timmerman D; Christiaens MR; Vergote I; Van Limbergen E; Carbonez A; Van Huffel S; Ameye L; Paridaens R
    Anticancer Drugs; 2004 Sep; 15(8):753-60. PubMed ID: 15494636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Optimal adjuvant hormone therapy in postmenopausal women with hormone-sensitive mammary carcinoma: tamoxifen and the aromatase inhibitors anastrozole, exemestane and letrozole].
    van Nes JG; Seynaeve C; van de Velde CJ; Nortier JW
    Ned Tijdschr Geneeskd; 2006 Dec; 150(52):2863-9. PubMed ID: 17319217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer.
    Perez EA
    Ann Oncol; 2007 Sep; 18 Suppl 8():viii26-35. PubMed ID: 17890211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer.
    Jordan VC; Brodie AM
    Steroids; 2007 Jan; 72(1):7-25. PubMed ID: 17169390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
    Pistelli M; Mora AD; Ballatore Z; Berardi R
    Curr Oncol; 2018 Apr; 25(2):e168-e175. PubMed ID: 29719441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer.
    Dixon JM
    Expert Rev Anticancer Ther; 2008 Mar; 8(3):453-63. PubMed ID: 18366292
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Menopausal symptoms and adjuvant therapy-associated adverse events.
    Hadji P
    Endocr Relat Cancer; 2008 Mar; 15(1):73-90. PubMed ID: 18310277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [New options in adjuvant endocrine therapy in breast cancer].
    Saltel-Fulero A; Donnadieu A; Leman-Detours S; Cottu P
    Bull Cancer; 2016 Jan; 103(1):104-12. PubMed ID: 26675809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reducing the risk for breast cancer recurrence after completion of tamoxifen treatment in postmenopausal women.
    Jahanzeb M
    Clin Ther; 2007 Aug; 29(8):1535-47. PubMed ID: 17919537
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.